Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231008 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
A Phase 2 study of Smith-Magenis Syndrome and Circadian, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT02231008 is a Phase 2 study of Smith-Magenis Syndrome and Circadian that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 49 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT02231008, a Phase 2 study of Smith-Magenis Syndrome and Circadian, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tasimelteon
Study Locations (4)
Maryland
- - Baltimore
- - Chevy Chase
California
- - Santa Monica
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-09 |
| Est. Completion | 2022-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02231008
The ClinicalTrials.gov registry entry for NCT02231008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Smith-Magenis Syndrome appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02231008 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Maryland, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02231008 about?
NCT02231008 is a clinical study titled "Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS". The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.
What is the current status of trial NCT02231008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2015-09. Estimated completion is 2022-01.
What conditions does trial NCT02231008 study?
This clinical trial studies the following conditions: Smith-Magenis Syndrome, Circadian.
What interventions are being tested in trial NCT02231008?
The interventions under investigation include: placebo (DRUG), tasimelteon (DRUG).
Who is sponsoring clinical trial NCT02231008?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02231008 being conducted?
This trial has 4 study locations across California, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smith-Magenis Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.